Innovus Pharmaceuticals will launch a fluticasone propionate nasal spray under the brand name FlutiCare in the US by the end of 2017 after acquiring rights to the product from West-Ward Pharmaceuticals International Limited (WWPIL). The 50μg per spray FlutiCare is equivalent to GSK's Flonase, and the company said that it expects revenue from sales of the product in … [Read more...] about Innovus Pharmaceuticals acquires US rights to fluticasone propionate nasal spray from West-Ward
Business
Savara receives US and Canadian patents for AeroVanc
The US Patent and Trademark Office has issued US Patent No. 9,572,774, titled "Dry Powder Vancomycin Compositions and Associated Methods," to inhaled drug developer Savara, Inc., the company said. In its statement, the company added, "This affords Savara important composition of matter protection for its AeroVanc program in the US, the largest market for the … [Read more...] about Savara receives US and Canadian patents for AeroVanc
Proveris Scientific joins IPAC-RS as an associate member
Aerosol characterization specialist Proveris Scientific has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an associate member, the company announced. IPAC-RS now has a total of 16 member pharmaceutical companies and 5 associate members. Proveris Scientific CEO Dino Farina commented, “We are excited to join … [Read more...] about Proveris Scientific joins IPAC-RS as an associate member
AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease
AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris's inhaled anticalin therapies, Pieris said. In the near term, AstraZeneca will also provide $12.5 million for a Phase 1 trial of Pieris's lead candidate PRS-060, which is expected to … [Read more...] about AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease
NIH announces funding opportunity for nasal delivery of CNS therapeutics
The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business Technology Transfer (STTR) program Both FOAs say that their purpose is to "is to develop a nasal delivery formulation … [Read more...] about NIH announces funding opportunity for nasal delivery of CNS therapeutics
Teva launches AirDuo RespiClick and authorized generic simultaneously in US
Teva has launched both the AirDuo RespiClick fluticasone propionate/salmeterol DPI and an authorized generic version of the product in the US, the company said. The FDA approved 3 doses of AirDuo RespiClick for the treatment of asthma in patients aged 12 years and over earlier this year. The company said that it expects the majority of sales to come from the … [Read more...] about Teva launches AirDuo RespiClick and authorized generic simultaneously in US
Invion announces deal with the Cho Group
Invion has announced that Hong Kong based The Cho Group will acquire 15.03% of Invion for a total of A$656,682 through a private placement. A restructuring of Invion's board will include the addition of two members of The Cho Group. According to Invion, "The company intends to use the proceeds of the investment for working capital as it continues to market the … [Read more...] about Invion announces deal with the Cho Group
United Therapeutics to collaborate with Respira on development of RT234 DPI for the treatment of pulmonary hypertension
Respira Therapeutics has announced that United Therapeutics will fund the development of Respira's RT234 DPI for the treatment of pulmonary hypertension. United Therapeutics will get an exclusive license for the product in North America and will be the lead investor in Respira's Series B financing round. Respira will continue to develop RT234 for other … [Read more...] about United Therapeutics to collaborate with Respira on development of RT234 DPI for the treatment of pulmonary hypertension
MVP announces distribution deals for spacers in US and for Penthrox inhaler in Russia
Medical Developments International (MVP) has announced distribution deals for its compact anti-static space chambers in the US and for its Penthrox methoxyflurane inhaler in Russia. All Walmart and Kmart pharmacies in the US will carry MVP spacers. In Russia, JSC Lancet will be the distributor for Penthrox in a deal that includes milestone payments of AUD $2.3 … [Read more...] about MVP announces distribution deals for spacers in US and for Penthrox inhaler in Russia
Amneal Pharmaceuticals launches generic mometasone furoate nasal spray
Amneal Pharmaceuticals initiated shipments of its generic version of Nasonex mometasone furoate nasal spray on April 4, 2017, the company said. According to Amneal, the mometasone furoate nasal spray is its "first pharmaceutical product in spray form"; the company also markets a generic tobramycin inhalation solution. Amneal Executive VP of Sales and … [Read more...] about Amneal Pharmaceuticals launches generic mometasone furoate nasal spray